EPO therapy has the potential to improve the lives of individuals with SCA by enhancing their oxygen-carrying capacity, reducing the frequency of complications, and ultimately extending their life expectancy. The gene discussed is EPO; the disease is autosomal dominant cerebellar ataxia.